



GenMark Diagnostics to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

November 8, 2017

CARLSBAD, Calif.--(BUSINESS WIRE)--Nov. 7, 2017-- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief Executive Officer, Hany Massarany, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum in New York, NY.

Mr. Massarany will participate in an analyst-led fireside chat on Thursday, November 9, at 3:00 PM Eastern Time. Interested parties may access a live and archived webcast of the event at ir.genmarkdx.com.

About GenMark Diagnostics

GenMark Diagnostics (NASDAQ:GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark's ePlex: *The True Sample-to-Answer Solution*™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20171107006919/en/>

Source: GenMark Diagnostics, Inc.

Investor Relations Contact

GenMark Diagnostics, Inc.
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
investors@genmarkdx.com